Chimeric Therapeutics Reports Lapse of Performance Rights and Options
CHM: $0.003 +0.00% · MC: $442K
Chimeric Therapeutics reported that performance rights and options lapsed after their conditions were not met or could no longer be satisfied. The company also gave notice of its virtual annual general meeting, scheduled for November, where shareholders will consider a proposed additional share-issue capacity of up to 10% and the re-election of director Phillip Hains.

Comments